Show simple item record

dc.contributor.authorFandos, N
dc.contributor.authorPérez-Grijalba, V
dc.contributor.authorPesini, P
dc.contributor.authorOlmos, S
dc.contributor.authorBossa, M
dc.contributor.authorVillemagne, VL
dc.contributor.authorDoecke, J
dc.contributor.authorFowler, C
dc.contributor.authorMasters, CL
dc.contributor.authorSarasa, M
dc.contributor.authorAIBL Research Group,
dc.date.accessioned2020-12-17T04:09:17Z
dc.date.available2020-12-17T04:09:17Z
dc.date.issued2017
dc.identifierpii: S2352-8729(17)30043-X
dc.identifier.citationFandos, N., Pérez-Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., Doecke, J., Fowler, C., Masters, C. L., Sarasa, M. & AIBL Research Group, (2017). Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals.. Alzheimers Dement (Amst), 8 (1), pp.179-187. https://doi.org/10.1016/j.dadm.2017.07.004.
dc.identifier.issn2352-8729
dc.identifier.urihttp://hdl.handle.net/11343/255185
dc.description.abstractINTRODUCTION: Plasma amyloid β (Aβ) peptides have been previously studied as candidate biomarkers to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. METHODS: Free and total Aβ42/40 plasma ratios (FP42/40 and TP42/40, respectively) were determined using ABtest assays in cognitively normal subjects from the Australian Imaging, Biomarker and Lifestyle Flagship Study. This population was followed-up for 72 months and their cortical Aβ burden was assessed with positron emission tomography. RESULTS: Cross-sectional and longitudinal analyses showed an inverse association of Aβ42/40 plasma ratios and cortical Aβ burden. Optimized as a screening tool, TP42/40 reached 81% positive predictive value of high cortical Aβ burden, which represents 110% increase over the population prevalence of cortical Aβ positivity. DISCUSSION: These findings support the use of plasma Aβ42/40 ratios as surrogate biomarkers of cortical Aβ deposition and enrichment tools, reducing the number of subjects submitted to invasive tests and, consequently, recruitment costs in clinical trials targeting cognitively normal individuals.
dc.languageeng
dc.publisherWiley
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titlePlasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals.
dc.typeJournal Article
dc.identifier.doi10.1016/j.dadm.2017.07.004
melbourne.affiliation.departmentFlorey Department of Neuroscience and Mental Health
melbourne.affiliation.departmentMedicine (Austin & Northern Health)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
melbourne.source.volume8
melbourne.source.issue1
melbourne.source.pages179-187
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1244170
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602863
melbourne.contributor.authorVillemagne, Victor
melbourne.contributor.authorFowler, Christopher
melbourne.contributor.authorMasters, Colin
dc.identifier.eissn2352-8729
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record